I'll answer each question systematically based on the paper content provided.

"""
Question: 1101

Evidence: This study was supported by Molecular Network Analysis and Social Network Exploration of HIV-1 Infection Transmission among Young Students in Jiangsu Province (0701-184160070478). The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

Rationale: The paper describes original research conducted in Jiangsu Province in 2021, including molecular epidemiological investigation and questionnaire survey. It mentions that datasets are available in online repositories and describes specific funding support, indicating this is previously unpublished data from their original research.

Answer: Yes
"""

"""
Question: 1102

Evidence: 242 Pol genes were amplified from 345 specimens, and ten genotypes were detected. The Pol gene (Reverse transcriptase and protease) was amplified and sequenced to identify the genotypes and DR profiles among LLV patients in 2021.

Rationale: The paper explicitly states that they amplified and sequenced the Pol gene from HIV specimens, and detected ten different genotypes, confirming they report HIV sequences.

Answer: Yes
"""

"""
Question: 1103

Evidence: NA

Rationale: After thoroughly reviewing the paper content, there is no mention of in vitro passage experiments being conducted. The study focuses on clinical samples from patients, not laboratory passage experiments.

Answer: No
"""

"""
Question: 1104

Evidence: NA

Rationale: The paper reports drug resistance analysis through genotypic testing and mutation analysis, but does not mention in vitro antiretroviral susceptibility testing or phenotypic susceptibility data.

Answer: No
"""

"""
Question: 2101

Evidence: The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

Rationale: The paper mentions that datasets are available in online repositories with accession numbers, but does not explicitly list GenBank accession numbers in the main text. The accession numbers are referenced as being in the article/Supplementary Material.

Answer: NA
"""

"""
Question: 2102

Evidence: The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

Rationale: The paper mentions datasets in online repositories but does not specify whether these are for laboratory HIV isolates or clinical isolates. Since the study used clinical samples from LLV patients, they are likely clinical isolates, but this cannot be definitively determined from the provided text.

Answer: NA
"""

"""
Question: 2103

Evidence: The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

Rationale: The paper states that accession numbers can be found in the article/Supplementary Material, but does not list any specific GenBank accession numbers in the main text provided.

Answer: NA
"""

"""
Question: 2202

Evidence: According to the drug resistance analysis results, 66 drug resistance mutation (DRM) sites were detected in 98 patients with drug resistance. Fifty-four DRM sites were detected in the reverse transcription (RT) region, including 25 NRTIs related sites with 125 mutations.

Rationale: The paper provides detailed information about drug resistance mutations found in individual patients, including specific mutation sites and frequencies, indicating they report lists of mutations for individual sequenced HIV isolates.

Answer: Yes
"""

"""
Question: 2301

Evidence: Ten HIV-1 genotypes were detected based on the Pol gene fragments from 242 cases.

Rationale: The paper specifically mentions studying HIV-1 genotypes, indicating they worked with HIV species HIV-1.

Answer: HIV-1
"""

"""
Question: 2302

Evidence: A total of 10 HIV-1 genotypes were detected, the proportion from high to low were as follows: Circulating Recombinant Forms (CRF) 01_AE (94, 38.8%), CRF07_BC (85, 35.1%), B (21, 8.7%), CRF67_01B (14, 5.8%), CRF08_BC (13, 5.4%), CRF55_01B (5, 2.1%), CRF68_01B (4, 1.7%), 01BC (4, 1.7%), 0107 (1, 0.4%) and CRF65_cpx (1, 0.4%).

Rationale: The paper explicitly lists all the subtypes detected in the study population, providing the specific subtypes and their frequencies.

Answer: CRF01_AE, CRF07_BC, B, CRF67_01B, CRF08_BC, CRF55_01B, CRF68_01B, 01BC, 0107, CRF65_cpx
"""

"""
Question: 2303

Evidence: The Pol gene (Reverse transcriptase and protease) was amplified and sequenced to identify the genotypes and DR profiles among LLV patients in 2021.

Rationale: The paper clearly states that they sequenced the Pol gene, which includes both Reverse transcriptase and protease regions.

Answer: Pol gene (Reverse transcriptase and protease)
"""

"""
Question: 2304

Evidence: 242 Pol genes were amplified from 345 specimens, and ten genotypes were detected. The DR rate was 40.5%, with 66, 86, and 14 being resistant to NRTIs, NNRTIs, and PIs, respectively.

Rationale: The paper extensively reports results from HIV pol sequences, including drug resistance analysis based on pol gene sequencing.

Answer: Yes
"""

"""
Question: 2401

Evidence: A cross-sectional study design was used to study the DR profiles in LLV patients who were followed up in Jiangsu Province in 2021. Inclusion criteria included: (1) Management (treatment and follow-up) in Jiangsu Province.

Rationale: The paper clearly states that all study participants were managed and followed up in Jiangsu Province, China, indicating the geographic origin of the sequences.

Answer: Jiangsu Province, China
"""

"""
Question: 2402

Evidence: A cross-sectional study design was used to study the DR profiles in LLV patients who were followed up in Jiangsu Province in 2021. The follow-up period was from January 2021 to December 2021.

Rationale: The paper explicitly states that samples were collected and patients were followed up during 2021.

Answer: 2021
"""

"""
Question: 2502

Evidence: PCR products were sent to Sangon Biotech for sequencing.

Rationale: While the paper doesn't explicitly state "Sanger sequencing," it describes traditional PCR amplification and sending products for sequencing, which is consistent with Sanger sequencing methodology. The methods section describes conventional PCR-based approaches without mentioning NGS technologies.

Answer: Yes
"""

"""
Question: 2503

Evidence: NA

Rationale: The paper describes traditional PCR amplification and sequencing methods but does not mention any next-generation sequencing (NGS) technologies being used.

Answer: No
"""

"""
Question: 2504

Evidence: NA

Rationale: The paper does not mention any cloning procedures being performed prior to sequencing of the samples.

Answer: No
"""

"""
Question: 2505

Evidence: NA

Rationale: The paper does not mention single genome sequencing being performed on the samples.

Answer: No
"""

"""
Question: 2506

Evidence: NA

Rationale: The paper does not mention molecular cloning being performed on the samples.

Answer: No
"""

"""
Question: 2601

Evidence: The samples of this study were collected by the drug resistance monitoring program for HIV/AIDS patients in Jiangsu Province. The collected specimens were extracted by the Lizhu automatic nucleic acid extractor (4-channel).

Rationale: The paper describes collecting plasma specimens and extracting nucleic acid from them, indicating plasma HIV sequencing was performed.

Answer: Yes
"""

"""
Question: 2602

Evidence: NA

Rationale: The paper specifically mentions plasma sample collection and nucleic acid extraction from plasma, but does not mention PBMC collection or sequencing from PBMC DNA.

Answer: No
"""

"""
Question: 2603

Evidence: In this study, a total of 345 samples were collected throughout 2021. After nucleic acid extraction, PCR amplification and sequencing were performed on the plasma of 345 samples, Pol genes of 255 patients were obtained.

Rationale: The paper states that 345 plasma samples were collected and underwent sequencing attempts, with 255 Pol genes obtained initially.

Answer: 345
"""

"""
Question: 2604

Evidence: NA

Rationale: The paper does not mention PBMC virus sequencing being performed.

Answer: 0
"""

"""
Question: 2605

Evidence: ART time at follow-up was more than 6 months; VL was in the range of 50--1,000 copies/ml during follow-up. According to WHO guidelines, LLV is defined as viral load (VL) between 50 and 1,000 copies/ml.

Rationale: The paper specifically studies Low-Level Viremia (LLV) patients with viral loads between 50-1,000 copies/ml, indicating active HIV replication.

Answer: Yes
"""

"""
Question: 2606

Evidence: NA

Rationale: The paper describes sequencing from plasma RNA, not from proviral DNA reservoirs in cells.

Answer: No
"""

"""
Question: 2701

Evidence: The subjects were older than 18 years at follow-up; age 18 and above.

Rationale: The inclusion criteria explicitly state that all subjects were 18 years or older, indicating no infants or children were included.

Answer: No
"""

"""
Question: 2702

Evidence: NA

Rationale: The paper describes a cross-sectional study and questionnaire survey, but does not mention any clinical trials being conducted.

Answer: No
"""

"""
Question: 2703

Evidence: NA

Rationale: The paper does not mention any clinical trials, so it cannot be determined that all individuals were in a clinical trial.

Answer: No
"""

"""
Question: 3101

Evidence: In this study, a total of 345 samples were collected throughout 2021. After nucleic acid extraction, PCR amplification and sequencing were performed on the plasma of 345 samples, Pol genes of 255 patients were obtained. Thirteen cases of sequences with poor quality or unmatched information were removed, and 242 cases of sequences meeting the research requirements were finally included.

Rationale: The paper states that 345 samples were collected from individuals for sequencing attempts, with 242 successful sequences obtained.

Answer: 345
"""

"""
Question: 3102

Evidence: In this study, a total of 345 samples were collected throughout 2021. After nucleic acid extraction, PCR amplification and sequencing were performed on the plasma of 345 samples, Pol genes of 255 patients were obtained.

Rationale: The paper indicates that all 345 individuals had samples collected for sequencing attempts, though not all were successful.

Answer: Yes
"""

"""
Question: 4101

Evidence: ART time at follow-up was more than 6 months; the treatment duration was more than half a year (≥180 days) at the time of follow-up.

Rationale: The inclusion criteria require ART duration of more than 6 months for all participants, indicating all individuals were ART-experienced, not ART-naive.

Answer: No
"""

"""
Question: 4102

Evidence: ART time at follow-up was more than 6 months; the treatment duration was more than half a year (≥180 days) at the time of follow-up.

Rationale: The inclusion criteria explicitly state that all participants had been on ART for more than 6 months, confirming they were ART-experienced.

Answer: Yes
"""

"""
Question: 4103

Evidence: ART time at follow-up was more than 6 months; the treatment duration was more than half a year (≥180 days) at the time of follow-up.

Rationale: Since all participants had ART duration >6 months, there were no ART-naive individuals in the study.

Answer: No
"""

"""
Question: 4104

Evidence: ART time at follow-up was more than 6 months; the treatment duration was more than half a year (≥180 days) at the time of follow-up.

Rationale: The inclusion criteria require all participants to have ART duration >6 months, so there were no ART-naive individuals.

Answer: 0
"""

"""
Question: 4105

Evidence: NA

Rationale: While the paper provides current treatment regimen information, it does not mention having complete ART history information for all individuals, including previous regimens.

Answer: No
"""

"""
Question: 4201

Evidence: NA

Rationale: The paper studies ART-experienced patients with low-level viremia, not treatment-naive patients, so it does not report transmitted HIV drug resistance.

Answer: No
"""

"""
Question: 4202

Evidence: NA

Rationale: The paper studies ART-experienced patients, not pretreatment patients, so it does not report pretreatment HIV drug resistance.

Answer: No
"""

"""
Question: 4301

Evidence: The treatment regimens were divided into four categories. Patients using the 2NRTIs+NNRTIs regimen accounted for the highest proportion (57.1%, 56/98), with 39 patients resistant to NRTIs, ABC, FTC, and 3TC having the highest drug resistance frequency; 49 patients resistant to NNRTIs, and all were resistant to EFV and NVP. Patients using the 2NRTIs+PIs regimen accounted for 28.6% (28/98).

Rationale: The paper describes patients receiving NRTIs, NNRTIs, PIs, and mentions INSTIs in the treatment regimen categories.

Answer: NRTIs, NNRTIs, PIs, INSTIs
"""

"""
Question: 4302

Evidence: 2NRTIs+INSTIs; INSTIs, Integrase Strand Transfer Inhibitors.

Rationale: The paper includes INSTIs as one of the treatment regimen categories mentioned in the methods and results.

Answer: Yes
"""

"""
Question: 4303

Evidence: 2NRTIs+PIs; PIs, Protease Inhibitors.

Rationale: The paper explicitly mentions patients receiving protease inhibitors as part of their treatment regimens.

Answer: Yes
"""

"""
Question: 4304

Evidence: The treatment regimens were divided into four categories: 2NRTIs+NNRITs, 2NRTIs+INSTIs, 2NRTIs+PIs, and Others.

Rationale: The paper shows that patients received different treatment regimens, indicating they did not all receive the same ART.

Answer: No
"""

"""
Question: 4305

Evidence: 2NRTIs+INSTIs; Treatment regimens: 2NRTIs+NNRITs, 2NRTIs+INSTIs, 2NRTIs+PIs, Others.

Rationale: The paper shows that some patients received INSTI-containing regimens (2NRTIs+INSTIs), so not all individuals were INSTI-naive.

Answer: No
"""

"""
Question: 4403

Evidence: NA

Rationale: The paper provides current treatment regimen information but does not provide information about whether patients received more than one ART regimen over time.

Answer: NA
"""

"""
Question: 4404

Evidence: NA

Rationale: The paper does not provide information about the number of ART regimens received by individuals.

Answer: NA
"""

"""
Question: 4405

Evidence: NA

Rationale: The paper does not provide information to determine if all individuals received the same number of ART regimens.

Answer: NA
"""

"""
Question: 4406

Evidence: NA

Rationale: The paper does not provide information to determine if all individuals received only one ART regimen.

Answer: NA
"""

"""
Question: 4501

Evidence: NA

Rationale: The paper does not specifically mention dolutegravir use among the individuals.

Answer: NA
"""

"""
Question: 4502

Evidence: DRV, Darunavir; PIs drugs: ATV, Atazanavir; DRV, Darunavir; FPV, Fosamprenavir; IDV, Indinavir; LPV, Lopinavir; NFV, Nelfinavir; SQV, Saquinavir; TPV, Tipranavir.

Rationale: The paper mentions darunavir (DRV) in the context of drugs tested for resistance, but does not specify how many individuals received darunavir.

Answer: NA
"""

"""
Question: 5101

Evidence: There are 98 drug resistance sequences among 242 pol genes (low or above level resistance to any class of drugs), and the drug resistance rate was 40.5% (98/242).

Rationale: The paper explicitly states that 98 individuals had drug resistance mutations out of 242 sequenced.

Answer: 98
"""

"""
Question: 5102

Evidence: NA

Rationale: The paper does not report any INSTI-resistance mutations in the results.

Answer: 0
"""

"""
Question: 5103

Evidence: TDF, Tenofovir; TDF resistance: 14, 7, 0, 2 for different regimens respectively, total 23.

Rationale: The paper reports that 23 patients had resistance to TDF (Tenofovir) across different treatment regimens.

Answer: 23
"""

"""
Question: 5104

Evidence: NA

Rationale: The paper does not report any INSTI-resistance mutations in the results section.

Answer: NA
"""

"""
Question: 6101

Evidence: NA

Rationale: The paper does not mention any phenotypic susceptibility testing being performed.

Answer: NA
"""

"""
Question: 6102

Evidence: NA

Rationale: The paper does not report any IC50 or IC90 values, as it focused on genotypic rather than phenotypic testing.

Answer: No
"""

"""
Question: 6103

Evidence: NA

Rationale: The paper does not report any IC50 fold change values, as it focused on genotypic testing.

Answer: No
"""

"""
Question: 6104

Evidence: NA

Rationale: The paper does not describe any phenotypic susceptibility assays being used.

Answer: NA
"""

"""
Question: 6105

Evidence: NA

Rationale: The paper does not mention replication capacity testing.

Answer: No
"""

"""
Question: 6106

Evidence: NA

Rationale: The paper does not mention phenotypic susceptibility testing for any drugs.

Answer: NA
"""

"""
Question: 7101

Evidence: NA

Rationale: The paper describes sequencing from clinical samples of LLV patients, not site-directed mutants created in the laboratory.

Answer: No
"""

"""
Question: 7102

Evidence: NA

Rationale: The paper does not mention any in vitro passage experiments being conducted.

Answer: No
"""